NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Recruiting 9 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

Timeline

Start: 2024-07-17
Primary completion: 2024-07-26
Completion: 2026-03-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belumosudil	Small molecule	—	Other

Indications

No indication recorded.